Translational and Clinical Research |Clinical Trials

The aim of the study is to identify any changes in the HBV DNA that might be associated with resistance to TDF, to determine how long any changes take to occur and to determine the effect of these changes on the clinical response to TDF.  It also looked at rates and patterns of HBsAg loss in this population after commencing HBV-active antiretroviral therapy (ART) and determinants of this.  This study recruited patients who are co-infected with HIV and HBV, and are currently taking, or who are about to commence, the anti-HIV drug TDF. The study cohort included HIV-HBV co-infected individuals from the Alfred Hospital, Melbourne Sexual Health Clinic, St Vincent's Hospital, Sydney and HIV-NAT/Thai Red Cross AIDS Research Centre, Bangkok, Thailand.

Principal Investigators

A/Prof Joe Sasaduesz and Prof Sharon Lewin
+61 3 9342 9047
j.sasadeusz@mh.org.au